基于倾向性评分匹配法比较甘精胰岛素生物仿制药与原研药治疗2型糖尿病的有效性与安全性

扫码查看

原文链接

万方数据

中文摘要：目的比较甘精胰岛素注射液生物仿制药与原研药在治疗2型糖尿病时的有效性与安全性.方法采用回顾性队列研究,收集2022年1月1日-2023年9月30日在山东中医药大学附属医院住院2次及以上且住院间隔大于3个月的应用甘精胰岛素的2型糖尿病患者的相关临床信息,采用倾向性评分匹配法(PSM),根据患者基线水平进行1∶1匹配.比较2组患者用药至少3个月后的有效性及安全性.有效性研究指标为糖化血红蛋白(HbAlc)的变化值,空腹血糖(FBG)的变化值及HbAlc＜7％的达标率.安全性指标为低血糖和皮疹瘙痒等发生率.结果 PSM前仿制药组患者67例,原研药组64例,2组年龄、糖尿病病程、合并使用非胰岛素降糖药物等方面有显著差异(P＜0.05).PSM后2组患者各42例,基线资料比较无明显差异.经统计分析,两组患者HbAlc的降低值、FBG降低值及HbAlc＜7％的达标率方面无统计学差异,低血糖、皮疹瘙痒等的发生率,两组差异也无统计学差异.结论甘精胰岛素生物仿制药治疗2型糖尿病的有效性和安全性不劣于原研药.

外文标题：Comparison of efficacy and safety of generic and original insulin glargine in treatment of type 2 diabetes by propensity score matching

外文摘要：Objective To compare the efficacy and safety between generic and original insulin glargine in treatment of type 2 diabetes.Methods Retrospective cohort study was used to collect the information of type 2 diabetes patients who used insulin glargine and were hospitalized twice or more from January 1st,2022 to September 30th,2023.The propensity score matching(PSM)was used to balance the baseline levels of covariates between the generic and original insulin glargine groups.The efficacy and safety of two groups were compared after at least three months.The primary outcome was the change of HbAlc from the baseline,and the secondary outcome was the change of fasting blood glucose(FBG)from baseline and the standard-reaching rate of HbAlc＜7.0％.Safety was assessed based on adverse events that included hypoglycemia,and rash.Results Before PSM,there were significant differences between the two groups in age,duration of diabetes,combination use of other antidiabetic agents(P＜0.05).After PSM,there were not statistically significant between two groups at baseline.The differences between the original group and the generic group in the reduction of HbAlc,the reduction of FBG and the standard-reaching rate of HbAlc 7.0％were not statistically significant.There was also no statistically significant difference in the incidence of hypoglycemia and rash between the two groups.Conclusion The efficacy and safety of generic insulin glargine in the treatment of type 2 diabetes are not inferior to the original drug.

外文关键词：

generic and original insulin glarginebiosimilarsoriginal drugefficacysafetypropensity score matching

作者：

金秋阳、朱明亮、刘群、辛义周

展开 >

作者单位：

山东中医药大学附属医院药学部,山东济南 250011

关键词：

甘精胰岛素注射液生物仿制药原研药有效性安全性倾向匹配法

基金：

山东省药品临床综合评价项目齐鲁卫生与健康领军人才项目(2019)山东省中医药科技重点项目山东省医学会临床药学科研专项山东省医药卫生科技项目

项目编号：

2022YZ003Z-2023052YXH2022ZX013202313010888

出版年：

2024

DOI：

10.7501/j.issn.1674-6376.2024.10.020

药物评价研究

天津药物研究院中国药学会

药物评价研究

CSTPCD北大核心

影响因子：1.199

ISSN：1674-6376

年,卷(期)：2024.47(10)